Edwards Lifesciences financials
$88.08+1.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.27B | $1.24B |
| Gross profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $1.02B | $992.8M |
| Gross margin | 77.5% | 78.0% | 78.1% | 77.8% | 77.5% | 78.7% | 78.9% | 80.6% | 79.9% | 78.4% | 80.2% | 79.8% |
| Operating income | $513.2M | $477.6M | $96.8M | $334.6M | $411.2M | $394.8M | $289.9M | $373.0M | $366.5M | $349.0M | $346.8M | $365.9M |
| Net income | $241.9M | $380.7M | $91.2M | $291.1M | $333.2M | $358.0M | $385.6M | $3.07B | $366.3M | $351.9M | $369.9M | $384.9M |
| Net margin | 13.9% | 23.1% | 5.8% | 18.7% | 21.7% | 25.3% | 27.8% | 226.7% | 26.7% | 26.5% | 29.2% | 31.0% |
| Diluted EPS | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 |
| EBITDA | $562.2M | $555.6M | $398.7M | $464.3M | $469.0M | $446.5M | $373.2M | $451.2M | $414.2M | $396.4M | $356.7M | $405.0M |
| Operating cash flow | $651.9M | $43.8M | $450.9M | $573.7M | $290.2M | $280.4M | -$127.5M | $351.8M | $371.5M | -$53.5M | $136.6M | $411.5M |
| Free cash flow | $585.0M | -$21.1M | $353.5M | $516.2M | $240.9M | $224.4M | -$177.3M | $299.9M | $286.1M | -$118.8M | $48.3M | $356.2M |
| Diluted shares | 577.6M | 580.7M | 581.8M | 585.7M | 587.9M | 587.8M | 590.7M | 598.1M | 604.3M | 604.1M | 606.9M | 609.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B |
| Short-term investments | $1.35B | $1.23B | $1.29B | $1.16B | $789.4M | $757.9M |
| Total debt | $598.7M | $598.5M | $598.3M | $598.2M | $598.0M | $597.8M |
| Total assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B |
| Total liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B |
| Shareholders' equity | $10.72B | $10.33B | $10.34B | $10.21B | $10.61B | $10.19B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology